Showing 111-120 of 2500 results for "".
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Upcoming Skin Cancer Champions Webinar Addresses Impact of AIhttps://practicaldermatology.com/news/Upcoming-Skin-Cancer-Champions-Webinar-Addresses-Impact-AI/2475627/Veronica Rotemberg, MD, PhD, will host a free webinar on the future of non-melanoma skin cancer care August 5 at 1:00 PM ET, Skin Cancer Champions announced. Dr. Rotemberg, Director of Dermatology Imaging Informatics for Memorial Sloan Kettering Cancer Center, will present “The Future of S
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://practicaldermatology.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Neoadjuvant Ipilimumab and Nivolumab Therapy Improves Survival in Stage III Melanomahttps://practicaldermatology.com/news/neoadjuvant-ipilimumab-and-nivolumab-therapy-improves-survival-stage-iii-melanoma/2467064/New phase 3 study results from the NADINA study suggest that neoadjuvant (neoadj) therapy with ipilimumab (IPI) and nivolumab (NIVO) followed by response-driven adjuvant therapy was associated with increased event-free survival (EFS) in patients with macroscopic stage III melanoma. The re
- FDA Approves New Humira Biosimilar for Multiple Inflammatory Conditionshttps://practicaldermatology.com/news/fda-approves-new-adalimumab-adbm-formulation-multiple-inflammatory-conditions/2462933/Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company, the approval enables an expansion of treatment options for chronic inflammatory diseases. This f
- Biosimilar News: YUFLYMA Added to CarePartners Specialty Pharmacy Cost Savings Programshttps://practicaldermatology.com/news/biosimilar-news-yuflyma-added-to-carepartners-specialty-pharmacy-cost-savings-programs/2462100/Celltrion USA, Inc.’s US Food and Drug Administration-approved biosimilar, YUFLYMA (adalimumab-aaty) has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira (adal
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Biosimilar News: Sandoz Launches Humira Biosimilar Hyrimoz in the U.S.https://practicaldermatology.com/news/biosimilar-news-sandoz-launches-humira-biosimilar-hyrimoz-in-the-us/2461832/Sandoz’s a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection is now available in the U.S. Hyrimoz HCF (100 mg/mL) is approved to treat all indications no longer covered by the regulatory exclusivity for the reference medicine, H
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB